ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.405,20
0,51%
S&P 500
5.987,37
0,30%
Dow Jones
44.736,57
0,99%
Euro vs US Dollar
1,04778
0,15%
Bitcoin
93.890,58
0,86%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. XTL Biopharmaceuticals Ltd (XTLB)

  7. XTL Biopharmaceuticals Ltd (XTLB) News

XTLB

XTL Biopharmaceuticals (XTLB)

XTL Biopharmaceuticals Ltd
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:XTLB
DatumZeitQuelleÜberschriftSymbolFirma
19/11/202423h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XTLBXTL Biopharmaceuticals Ltd
12/11/202415h15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XTLBXTL Biopharmaceuticals Ltd
15/10/202415h12Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XTLBXTL Biopharmaceuticals Ltd
14/08/202415h15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XTLBXTL Biopharmaceuticals Ltd
14/08/202415h15GlobeNewswire Inc.XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 MillionNASDAQ:XTLBXTL Biopharmaceuticals Ltd
22/07/202422h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XTLBXTL Biopharmaceuticals Ltd
12/06/202422h05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XTLBXTL Biopharmaceuticals Ltd
05/06/202415h20Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XTLBXTL Biopharmaceuticals Ltd
05/06/202415h15GlobeNewswire Inc.XTL Entered Definitive Agreement to Acquire The Social ProxyNASDAQ:XTLBXTL Biopharmaceuticals Ltd
13/05/202416h32Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XTLBXTL Biopharmaceuticals Ltd
20/03/202415h15GlobeNewswire Inc.XTL To Aquire The Social ProxyNASDAQ:XTLBXTL Biopharmaceuticals Ltd
15/11/202316h29Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XTLBXTL Biopharmaceuticals Ltd
20/10/202322h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XTLBXTL Biopharmaceuticals Ltd
20/10/202322h00GlobeNewswire Inc.XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in IsraelNASDAQ:XTLBXTL Biopharmaceuticals Ltd
20/10/202322h00GlobeNewswire Inc.XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyNASDAQ:XTLBXTL Biopharmaceuticals Ltd
10/08/202315h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XTLBXTL Biopharmaceuticals Ltd
16/05/202317h01Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
23/02/202320h30Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
01/02/202315h53Edgar (US Regulatory)Amended Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k/a)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
24/08/202216h31Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
30/03/202223h16Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
26/01/202218h43Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
19/01/202217h04Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
16/12/202123h17Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
24/11/202116h39Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
08/06/202112h05Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
19/05/202117h40Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
19/05/202117h31Edgar (US Regulatory)Amended Annual and Transition Report (foreign Private Issuer) (20-f/a)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
19/05/202117h26Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
07/01/202115h10Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
 Showing the most relevant articles for your search:NASDAQ:XTLB

Kürzlich von Ihnen besucht

NASDAQ
MSFT
Microsoft
TG
BAYN
Bayer
CCOM
SILVER
SILVER
COIN
ADAUSD
Cardano
CCOM
US100
US Tech 100
USOTC
DTEGY
Deutsche Telekom (QX)
DBI
TDXP
Tec DAX
TG
TUI1
Tui
COIN
BTCUSD
Bitcoin
TG
BAS
BASF
TG
RHM
Rheinmetall
NASDAQ
TSLA
Tesla
TG
NOV
Novo Nordisk
TG
D7G
Nel ASA
AMEX
SPY
SPDR S&P 500
TG
CBK
Commerzbank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten

BLACK FRIDAY

ADVFN

Seit 25 Jahren im Geschäft 1999-2024

Sparen Sie bis zu 60%* für Euronext Level 2

1 Jahr 40%, 2 Jahre 50% und *3 Jahre 60%

*Über 3 Jahre 1094.04€, jetzt nur noch 437.62€